CRDF Earnings

CRDF reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 120.00K against an estimate of 121.43K, resulting in a -1.18% surprise. The EPS was 0, surpassing the expected -0.2 by 0% . The stock experienced a 0.45% price change on the earnings day and a 2.23% change over the next five days, reflecting market reactions to the results.

Following CRDF's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 0.45% on the day of the release. Over the subsequent five days, it saw a 2.23% change. Historically, CRDF's stock price tends to shift by an average of -2.80% in the 10 days leading up to earnings and +17.04% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CRDF’s annual revenue to reach 105.56K, while the EPS is projected at -0.19. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 1.24% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CRDF's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 1.24%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CRDF's stock price typically moves by -2.80% in the 10 days before its earnings and +17.04% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.19 and revenue of 105.56K.

The earnings call presents a balanced picture. Financially, the company shows a solid cash position and runway, but faces risks from regulatory changes and market competition. The Q&A reveals positive clinical progress but lacks clarity on timelines, which could concern investors. The $40 million capital raise is a positive, but the absence of specific guidance and potential delays in trials offset this. Overall, the sentiment is neutral as positives are balanced by uncertainties and risks.